SCHEMBL23869840

SCHEMBL23869840

CN1CC[C@@](O)(C(C)(C)C)C1=O

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
METAP2 P50579 1/20 0.31
EHMT2 Q96KQ7 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23793964 1.00 GRIN1 (0.33) GRIN1GRIN2AMETAP2EHMT2ALDH1A1
SCHEMBL23869815 1.00 GRIN1 (0.33) GRIN1GRIN2AMETAP2EHMT2ALDH1A1
SCHEMBL23794163 0.88 GRIN1 (0.37) GRIN1GRIN2AEHMT2
SCHEMBL23869962 0.84 GRIN1 (0.32) GRIN1GRIN2AMETAP2
SCHEMBL23793962 0.78 CRBN (0.30)
SCHEMBL23869995 0.78 PTGS1 (0.33) METAP2
SCHEMBL23869977 0.76 PTGS1 (0.36)
SCHEMBL16478701 0.73
SCHEMBL30874276 0.72 GRIN1 (0.34) GRIN1GRIN2A
SCHEMBL16478702 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 US disclosed
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 US disclosed
US-11254673-B2 Small molecule inhibitors of NF-κB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2022-02-22 US disclosed
US-20210300918-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300918-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB GRIN1 4394/4885GRIN2A 4803/4885METAP2 2779/4885
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase NFKBIA, IKBKB, NFRKB GRIN1 4394/4885GRIN2A 4803/4885METAP2 2779/4885
US-11254673-B2 Small molecule inhibitors of NF-κB inducing kinase NFKBIA, IKBKB, CHUK GRIN1 4309/4885GRIN2A 4795/4885METAP2 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.